BHC vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BHC and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BHC is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | BHC | HLN |
|---|---|---|
| Company Name | Bausch Health Companies Inc. | Haleon plc |
| Country | Canada | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Pharmaceuticals | Personal Care Products |
| Market Capitalization | 2.35 billion USD | 40.25 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 29, 1994 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of BHC and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BHC | HLN |
|---|---|---|
| 5-Day Price Return | -3.04% | -0.84% |
| 13-Week Price Return | -4.79% | -11.02% |
| 26-Week Price Return | 2.05% | -14.92% |
| 52-Week Price Return | -19.82% | -12.92% |
| Month-to-Date Return | -0.22% | -0.63% |
| Year-to-Date Return | -23.06% | -12.48% |
| 10-Day Avg. Volume | 0.27M | 16.58M |
| 3-Month Avg. Volume | 0.42M | 14.61M |
| 3-Month Volatility | 55.99% | 19.16% |
| Beta | 1.19 | 0.45 |
Profitability
Return on Equity (TTM)
BHC
-96.76%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
BHC has a negative Return on Equity of -96.76%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
HLN
3.26%
Personal Care Products Industry
- Max
- 33.29%
- Q3
- 19.04%
- Median
- 10.69%
- Q1
- 3.26%
- Min
- -10.45%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BHC
0.99%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Falling into the lower quartile for the Pharmaceuticals industry, BHC’s Net Profit Margin of 0.99% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
HLN
12.84%
Personal Care Products Industry
- Max
- 14.65%
- Q3
- 10.84%
- Median
- 9.29%
- Q1
- 5.35%
- Min
- -0.14%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BHC
18.00%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
BHC’s Operating Profit Margin of 18.00% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.64%
- Q3
- 16.46%
- Median
- 12.80%
- Q1
- 8.01%
- Min
- 2.98%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BHC | HLN |
|---|---|---|
| Return on Equity (TTM) | -96.76% | 3.26% |
| Return on Assets (TTM) | 0.37% | 1.58% |
| Net Profit Margin (TTM) | 0.99% | 12.84% |
| Operating Profit Margin (TTM) | 18.00% | 19.64% |
| Gross Profit Margin (TTM) | 70.70% | 60.75% |
Financial Strength
Current Ratio (MRQ)
BHC
1.31
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
BHC’s Current Ratio of 1.31 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.87
Personal Care Products Industry
- Max
- 4.03
- Q3
- 2.73
- Median
- 1.76
- Q1
- 1.16
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BHC
44.72
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
With a Debt-to-Equity Ratio of 44.72, BHC operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
HLN
0.53
Personal Care Products Industry
- Max
- 1.80
- Q3
- 0.78
- Median
- 0.30
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BHC
1.12
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, BHC’s Interest Coverage Ratio of 1.12 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -3.28
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BHC | HLN |
|---|---|---|
| Current Ratio (MRQ) | 1.31 | 0.87 |
| Quick Ratio (MRQ) | 0.79 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 44.72 | 0.53 |
| Interest Coverage Ratio (TTM) | 1.12 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BHC
0.00%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
BHC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.99%
- Q3
- 2.70%
- Median
- 1.98%
- Q1
- 0.95%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
BHC
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
BHC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HLN
954.40%
Personal Care Products Industry
- Max
- 221.40%
- Q3
- 137.27%
- Median
- 70.48%
- Q1
- 51.10%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | BHC | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
BHC
24.18
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
BHC’s P/E Ratio of 24.18 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
HLN
20.40
Personal Care Products Industry
- Max
- 46.28
- Q3
- 31.71
- Median
- 22.50
- Q1
- 20.20
- Min
- 11.79
HLN’s P/E Ratio of 20.40 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BHC
0.24
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, BHC’s P/S Ratio of 0.24 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
HLN
2.62
Personal Care Products Industry
- Max
- 2.59
- Q3
- 2.35
- Median
- 1.92
- Q1
- 1.18
- Min
- 0.00
With a P/S Ratio of 2.62, HLN trades at a valuation that eclipses even the highest in the Personal Care Products industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
BHC
12.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
At 12.57, BHC’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
HLN
2.11
Personal Care Products Industry
- Max
- 12.00
- Q3
- 6.22
- Median
- 2.84
- Q1
- 1.70
- Min
- 1.12
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BHC | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.18 | 20.40 |
| Price-to-Sales Ratio (TTM) | 0.24 | 2.62 |
| Price-to-Book Ratio (MRQ) | 12.57 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 2.15 | 13.68 |